Almirall LLC
$946.1K 5,128 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Hikma Pharmaceuticals USA
Hikma Pharmaceuticals USA reported $953,328.80 across General Payments, Research, and Ownership to 3,664 physicians and teaching hospitals across 3,685 transactions.
- $953.3K Above-median payer
- All-tracks total
- 3,685 Top quartile volume
- Transactions
- 3,664 Top quartile reach
- Recipients
- −$6.9K
- General Payments vs PY2023
Hikma Pharmaceuticals USA reported $953,328.80 across all CMS Open Payments tracks (General + Research + Ownership) to 3,664 physicians and teaching hospitals in Program Year 2024 - ranking #627 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $501,181.54, averaging $260.19 per recipient.
How Hikma Pharmaceuticals USA's $953.3K all-tracks total breaks down
Hikma Pharmaceuticals USA's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
49/100
Total payments
F
19/100
Transaction volume
F
37/100
Physician reach
F
38/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer hikma-pharmaceuticals-usa Hikma Pharmaceuticals USA
$953.3K · #627/1,925 · 0.0% industry · PY2024
- TOT $953.3K
- RANK #627
- SHARE 0.0%
- TXN 3,685
- RCP 3,664
- CAT 8
- GEN $501.2K
- ΔGEN −$6.9K
- TOP1 13.2%
- PY 2024
Volume peers
Nearest volume peer: Almirall LLC ($946.1K)
Hikma Pharmaceuticals USA sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Hikma Pharmaceuticals USA's CMS-reported General Payments decreased by $6.9K (−1.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: HIKMA PHARMACEUTICALS USAPY2023: HIKMA PHARMACEUTICALS USAPY2024: Hikma Pharmaceuticals USA. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $508,096.31
- PY2024
- $501,181.54
What the Data Shows for Hikma Pharmaceuticals USA
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Hikma Pharmaceuticals USA, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 8-category general-payment breakdown below at $165.6K (33.0% of General Payments, 104 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 8 types of general payments, Hikma Pharmaceuticals USA's largest category was "Consulting Fee" at $165.6K - 33.0% of General Payments.
Hikma Pharmaceuticals USA reports 8 general-payment categories - the top three are Consulting Fee (33.0%), Travel and Lodging (30.6%), and Compensation for Services Other Than Consulting (18.6%). The remaining 5 categories make up 17.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Hikma Pharmaceuticals USA files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Hikma Pharmaceuticals USA divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $165.6K | 104 | 33.0% |
| Travel and Lodging | $153.2K | 58 | 30.6% |
| Compensation for Services Other Than Consulting | $93.0K | 22 | 18.6% |
| Food and Beverage | $66.5K | 3,343 | 13.3% |
| Charitable Contribution | $15.0K | 1 | 3.0% |
| Gift | $3.9K | 97 | 0.8% |
| Honoraria | $3.2K | 3 | 0.6% |
| Education | $721.00 | 36 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $179,640.71 (35.8%) of $501,181.54 in this company's General Payments records across 2,391 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Hikma Pharmaceuticals USA
The five named recipients with the highest reported General Payments from this company
- 1
Paul Hogya
$66,110.00 across 22 reported transactions
- 2
Elias Jabbour
$48,734.20 across 12 reported transactions
- 3
Robert Haddad
$22,052.83 across 4 reported transactions
- 4
Ralph Defronzo
$21,417.68 across 5 reported transactions
- 5
Hagop Kantarjian
$21,326.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Hikma Pharmaceuticals USA ranks #627 of 1,925 by total payments (top 33% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,346 of 1,838 by HHI (bottom 27% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Intrinsic Therapeutics : $300.7K total payments, HHI 441
- Braeburn Inc. : $1.2M total payments, HHI 439
- Arthrex, Inc. : $104.3M total payments, HHI 439
- Uoc USA Inc : $460.8K total payments, HHI 437
- ZOLL Respicardia, Inc. : $325.9K total payments, HHI 435
- Vasorum USA Inc. : $12.3K total payments, HHI 435
- Hikma Pharmaceuticals USA (this company) : $501.2K total payments, HHI 435
- Butterfly Network, Inc. : $100.3K total payments, HHI 434
- Acera Surgical, Inc. : $623.5K total payments, HHI 432
- Sirtex Medical Inc : $2.5M total payments, HHI 432
- Cycle Pharmaceuticals Inc : $34.4K total payments, HHI 430
- Eli Lilly and Company : $8.0M total payments, HHI 429
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Hikma Pharmaceuticals USA's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Hikma Pharmaceuticals USA.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Hikma Pharmaceuticals USA.
Showing 6 of 1,924 companies with CMS-reported payment data.
Heron Therapeutics, Inc.
$945.0K 4,695 recipients
Compare payment profiles
OrganOx Ltd
$944.6K 100 recipients
Compare payment profiles
Vascular Technology, Inc.
$943.2K 50 recipients
Compare payment profiles
Leica Microsystems Inc.
$942.6K 487 recipients
Compare payment profiles
NS Pharma, Inc.
$942.1K 369 recipients
Compare payment profiles
Put this to use
Hikma Pharmaceuticals USA ranks #627 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Hikma Pharmaceuticals USA sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Hikma Pharmaceuticals USA. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.